Author: admin

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

SUMMIT, N.J. – December 05, 2025 – (SeaPRwire) – Leapfrog Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units are expected to commence trading on December 5, 2025 on the Global Market tier of The Nasdaq Stock Market LLC under the symbol LFACU. The Company, which is led by Matthew R. Pollard, Abhay N. Pande and Kevin M. Murphy, is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Each unit sold in the offering consists of one Class A ordinary share (an “ordinary share”) and one half of one redeemable warrant with a strike price of $11.50 per ordinary share exercisable within 5 years of the Company completing an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and warrants are expected to be listed on the Global Market tier of The Nasdaq Stock Market LLC under the symbols “LFAC” and “LFACW,” respectively. BTIG, LLC is serving as the sole book-running manager of the offering. The underwriters have been granted a 45-day option to purchase up to an additional 1,875,000 units at the initial public offering price to cover over-allotments, if any. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering was made only by means of a prospectus, copies of which, when available, may be obtained by contacting BTIG, LLC, 65 East 55 Street, New York, NY 10022, by emailing ProspectusDelivery@btig.com, or by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Leapfrog Acquisition Corp Leapfrog Acquisition Corp is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or engaging in any other similar business combination with one or more businesses or entities. The Company is led by Chief Executive Officer, Matthew R. Pollard, President and Chief Investment Officer, Abhay N. Pande and Chief Financial Officer, Kevin M. Murphy. The Company will prioritize businesses in the international energy supply chain and critical minerals sectors, including their related infrastructure in its search for attractive merger candidates. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the anticipated use of the proceeds of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements, including those set forth in the risk factors section of the registration statement and prospectus for the Company’s initial public offering. Copies of these documents can be accessed through the SEC’s website at www.sec.gov. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law. Media Contact Company: Leapfrog Acquisition Corp Contact: Media Team Telephone: +1-201-379-4200 LinkedIn: https://www.linkedin.com/company/leapfrog-acquisition-corporation Email In the US: abhay@leapfrogspac.com Email In Asia: matt@leapfrogspac.com kevin@leapfrogspac.com

Hong Kong - 2025年12月01日 - (SeaPRwire) - 全球领先的现场食物垃圾消化技术公司 ORCA 宣布，与保得工程有限公司（Polytek Engineering Co. Ltd.）建立合作关系，成为其在香港的独家经销商及服务伙伴。此项合作标志着 ORCA 在香港持续扩张的重要一步，并支持其在大湾区及东南亚市场的更广泛布局。 应对香港的食物垃圾挑战 香港在废物管理方面持续面临重大挑战。2023 年，全港每天弃置的都市固体废物（MSW）平均达 10,884 公吨。食物垃圾依然是最大单一废物流，占比 29%，即每日约 3,191 公吨(info.gov.hk)。 政府已取得显著进展——2023 年家庭食物垃圾弃置量下降 12.6%，回收率则由前一年的 32% 上升至 33% (info.gov.hk)。 然而，商业及工业部门每天仍产生近 1,000 公吨的食物垃圾，突显需要具规模性、可持续的解决方案，以配合现有措施，并支持香港的长远减废目标 (epd.gov.hk)。 推动可持续发展的合作关系 ORCA 食物垃圾消化机提供现场处理方案，将食物垃圾转化为环保的排放水，减少运输排放、保护堆填区容量，并协助企业达成可持续发展指标。 保得工程是专业厨房、洗衣房及冷库系统的可靠领导者，拥有数十年设计、供应、安装及售后服务经验。他们在项目设计及构思阶段的角色，使其能够在新建或翻新项目中无缝整合 ORCA 技术，确保从一开始便纳入食物垃圾减量方案。 关于 ORCA ORCA 是现场食物垃圾消化技术的先驱，提供的系统可帮助企业减少对堆填区及运输的依赖、降低温室气体排放，并最终从源头减少食物垃圾。 “这项合作是解决香港迫切食物垃圾问题的重要一步。”ORCA CEO Louis Anagnostakos 表示，“虽然 ORCA 仍将继续作为独立的全球公司运营，但通过将我们的创新技术与保得的工程专长结合，我们能够加速可持续解决方案在商业领域及大湾区的应用。” 关于保得工程有限公司 保得工程有限公司是香港、澳门及中国内地领先的专业厨房、洗衣房及冷库解决方案供应商，业务涵盖设计、供应、安装及长期服务，为客户提供高性能、量身定制的方案。 “保得一直致力于提供高性能、面向未来的厨房及设施方案。”保得工程总经理曾志添（Joseph Tsang）表示，“通过此次独家合作，我们能够在项目最早的设计阶段引入 ORCA， 经过验证的食物垃圾技术，让客户从一开始便将可持续性融入其营运之中。”

Hong Kong – December 01, 2025 – (SeaPRwire) – ORCA, a global leader in on-site food-waste digestion technology, has partnered with Polytek Engineering Co. Ltd. as its exclusive distributor and service partner for Hong Kong. This collaboration marks an important step in ORCA’s continued expansion in Hong Kong and contributes to its wider presence throughout the Greater Bay Area and Southeast Asia markets. Addressing Hong Kong’s Food Waste Challenge Hong Kong continues to face significant challenges in waste management. In 2023, the city disposed of an average of 10,884 tonnes of municipal solids waste (MSW) per day. Food waste remained the largest single component, accounting for 29% or about 3,191 tonnes daily (info.gov.hk). The government has made commendable progress—household food waste disposal fell by 12.6%, and recovery rates increased to 33% in 2023, up from 32% the previous year (info.gov.hk). Still, the commercial and industrial sector contributes close to 1,000 tonnes of food waste daily, underscoring the need for scalable, sustainable solutions that can complement existing initiatives and support Hong Kong’s long-term waste reduction goals (epd.gov.hk). A Partnership for Sustainable Impact ORCA Digesters provide on-site solutions that convert food waste into environmentally safe water, reducing transportation emissions, protecting landfill capacity, and helping businesses meet sustainability targets. Polytek Engineering is a trusted leader in professional kitchen, laundry, and cold storage systems, with decades of expertise in design, supply, installation, and after-sales service. Their role at the design and conception phase of projects uniquely positions them to integrate ORCA technology into new builds and retrofits, ensuring food waste diversion is considered from the outset. About ORCA ORCA is a pioneer in on-site food waste digestion technology, offering systems that help businesses reduce landfill and transportation reliance, cut greenhouse gas emissions and ultimately reduce food waste at the source. “This partnership marks an important step toward addressing Hong Kong’s pressing food-waste challenge,” said Louis Anagnostakos — CEO, ORCA. “While ORCA continues to operate as an independent global company, by integrating our innovative technology with Polytek’s engineering expertise we can accelerate adoption of sustainable solutions across the commercial sector and the wider Greater Bay Area.” About Polytek Engineering Co. Ltd Polytek Engineering Co. Ltd is a leading provider of professional kitchen, laundry, and cold storage solutions in Hong Kong, Macau, and Mainland China. With expertise across design, supply, installation, and long-term service, Polytek delivers high-performance solutions tailored to client needs. “Polytek has always focused on delivering high-performance, future-ready kitchen and facility solutions,” said Joseph Tsang — General Manager, Polytek. “Through this exclusive partnership, we can now bring ORCA’s proven food waste technology into projects at the earliest design stage—helping our clients build sustainability directly into their operations from inception.”

New York, NY – November 22, 2025 – (SeaPRwire) – Innovative Warehouse Solutions (IWS), a leading New York-based eCommerce fulfillment company, has officially signed a partnership deal with Amazon Shipping, Amazon’s small parcel delivery network. Historically focused solely on supporting Amazon’s own eCommerce operations, Amazon Shipping now reaches 90% of the U.S. population with transit speeds that compete with UPS Ground and USPS Ground Advantage. In 2024 alone, the service delivered 5.7 billion packages, securing its position as the largest small parcel carrier in the U.S. by volume. Addressing questions about the unusual nature of a fulfillment company partnering with its biggest competitor, Brian Gibbons, CEO of IWS, emphasized that Amazon is a net positive for the entire eCommerce ecosystem. Now in his early 40s, Gibbons recalled a time when online shopping felt risky, noting that Amazon transformed the industry by introducing safety, trust, and standards. This foundation enabled a generation of entrepreneurs to launch businesses—from Shopify stores to multi-channel operations—with Gibbons adding, “We’re all kind of standing on Amazon’s shoulders.” Gibbons confirmed that most brands supported by IWS also sell on Amazon, framing the platform as a core channel akin to Sears or Macy’s in the 1990s, but not the sole revenue stream. “Smart brands diversify,” he explained, noting that IWS clients typically sell across Shopify, Amazon, Faire, Bloomingdale’s, and other platforms. IWS’s strength lies in its omni-channel fulfillment solution, which aggregates orders from all channels, leverages a centralized inventory pool, and tailors fulfillment to each channel’s unique requirements—resulting in lower holding costs and greater efficiency for brands. When asked what IWS offers that Amazon cannot, Gibbons acknowledged Amazon’s exceptional operational efficiency but highlighted customization as a key differentiator. Services like retail EDI, kitting, and channel-specific packaging are areas where third-party fulfillment providers like IWS deliver more value, as Amazon likely does not see sufficient ROI to prioritize these tailored offerings. Gibbons cited multiple factors driving the partnership with Amazon Shipping, starting with the stagnation of the small parcel 3PL industry over the past 20 years. While USPS’s Ground Advantage represented progress, legacy carriers continue to impose outdated surcharges—including residential delivery fees and fuel surcharges—even as residential deliveries have become standard. Amazon Shipping is disrupting this model by eliminating residential surcharges and offering deep discounts on fuel charges unless prices spike significantly, a change that Gibbons described as “huge for eCommerce brands.” Beyond cost, performance was a critical consideration. Gibbons noted that smaller carriers may offer attractive rates but often lack reach and speed, whereas Amazon Shipping provides 7-day-a-week delivery, faster windows for long-distance shipments, and employs uniformed drivers in branded trucks instead of gig workers. Additionally, the service includes delivery photo confirmation— a feature rarely offered at scale by other carriers. The partnership aligns with IWS’s mission to operate as an extension of its clients’ businesses: while clients manage product, marketing, and conversion, IWS handles logistics. This requires staying ahead of industry trends and identifying opportunities to enhance cost-effectiveness, speed, and reliability—all areas where Amazon Shipping excels. “In many cases, we’re giving our brands faster delivery at a lower cost,” Gibbons said. “That’s a no-brainer.” With this new partnership, IWS continues its commitment to providing flexible, tech-forward fulfillment solutions that empower growing eCommerce brands to thrive in an increasingly competitive market. Media contact Brand: Innovative Warehouse Solutions Contact: Media team Email: Info@invwhs.com Website: https://invwhs.com